BaroPace, Inc. Announced First Patient Enrolled in Non-Pharmacologic Hypertension and Heart Failure Treatment Trial
SAMMAMISH, Wash. — BaroPace Inc., a medical device company focused on the development of PressurePace™, a real-time physiologic control software and hardware to regulate cardiac pacemakers to treat resistant hypertension and heart failure with preserved ejection fraction (HFpEF), today announced that the first patient has been enrolled in the Company's First-in-Human (FIH) clinical trial, RelieveHFpEF-II.
公開済み : 2年前 沿って Sarjatha Shahinlal の Health
The Aerospace African Forum brings together decision makers and major players in the aerospace industry to discuss “Sustainable Mobilities”.
Casablanca, Morocco — The Moroccan city of Casablanca hosted today the first edition of the Aerospace African Forum,…
トピック: UAE